Lipids: Eprotirome shows promise as a novel way to target dyslipidemia

Nature Reviews Endocrinology

Volumn 6, Issue 7, 2010, Pages 354-

  Koch, Linda ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EPROTIROME; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; THYROID HORMONE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 77953970622     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.74     Document Type: Article

References (1)

1. Ladenson, P. W. et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med. 362, 906-916 (2010)